Base Editing Corrects a Genetic Disease for the First Time in Living Patients, Putting BEAM-302 on Track for FDA Accelerated Approval
Beam Therapeutics' BEAM-302 has achieved the first-ever in-vivo base editing correction of a disease-causing mutation in human patients, reaching therapeutic AAT levels in a Phase 1/2 trial for alpha-1 antitrypsin deficiency. A pivotal Q1 2026 data readout is now imminent.
Overview
For the first time in the history of gene editing, a living patient has had a disease-causing mutation corrected at the DNA level — not removed, disrupted, or silenced, but precisely rewritten. Beam Therapeutics’ experimental therapy BEAM-302 achieved this milestone in a Phase 1/2 clinical trial for alpha-1 antitrypsin deficiency (AATD), a rare genetic disorder that causes progressive lung and liver destruction in roughly 100,000 Americans with the most severe form of the disease.
The initial results, announced in March 2025, established clinical proof of concept for in vivo base editing — a refined variant of CRISPR that rewrites individual nucleotide “letters” in the genome without making double-strand cuts in the DNA. The company has since secured alignment with the FDA on an accelerated approval pathway and is expected to report an updated, expanded dataset before the end of the first quarter of 2026, according to Beam’s Q4 2025 financial results.
What We Know
AATD is caused primarily by a single-letter error in the SERPINA1 gene: an adenine where there should be a guanine at the position encoding amino acid 342 of the AAT protein. Patients who inherit two copies of this mutation — the PiZZ genotype — produce a misfolded Z-AAT protein that accumulates in the liver and fails to reach the lungs in adequate quantities. The result is simultaneous liver toxicity and progressive lung destruction from unchecked protease activity.
Current treatment consists of weekly or biweekly intravenous infusions of pooled human plasma-derived AAT protein, a therapy approved in 1987. It is expensive, burdensome, and addresses only the lung pathology; it does not prevent the liver damage caused by accumulated Z-AAT, and it does not correct the underlying genetic defect.
BEAM-302 uses an adenine base editor delivered via lipid nanoparticles that target liver cells. The editor converts the pathogenic adenine back to guanine directly in the genome of hepatocytes — converting the mutant Z-AAT-producing gene into a functional M-AAT-producing gene without breaking the DNA double helix. According to initial Phase 1/2 data from Beam, a single dose at the highest explored level (60 mg, three patients) achieved a mean total serum AAT of 12.4 micromolar at Day 28, exceeding the 11 micromolar protective threshold associated with clinical benefit. Mutant Z-AAT in circulation declined by a mean of 78 percent at the same dose.
At a 2025 scientific conference, Beam presented longer follow-up data showing the corrected M-AAT protein made up 91 percent of total circulating AAT at Day 28 in the 60 mg cohort — above the approximately 80 percent seen in the mildly affected heterozygous MZ genotype — while Z-AAT suppression reached 79 percent. A fourth cohort at 75 mg was subsequently initiated, and enrollment in a second study part for patients with concurrent mild-to-moderate liver disease was begun.
The safety profile across all nine patients in the first three dose cohorts was described as favorable by the company, with all adverse events rated mild to moderate, no serious adverse events, and no dose-limiting toxicities observed. Grade 1 transient liver enzyme elevations and mild infusion-related reactions occurred but resolved without intervention.
In January 2026, Beam disclosed that it had reached formal agreement with the FDA on an accelerated approval pathway for BEAM-302, under which biomarker endpoints — specifically serum AAT levels evaluated over 12 months — could support a biologics license application submission. The agency also accepted BEAM-302 into its Chemistry, Manufacturing, and Controls Development and Readiness Pilot program, which is reserved for products with expedited clinical development timelines.
What We Don’t Know
The Q1 2026 data readout that Beam has committed to remains forthcoming as of early March 2026. That dataset is expected to encompass more patients, longer follow-up, additional dose levels including the 75 mg cohort, and the first data from Part B of the trial involving patients with liver disease — the population for which current augmentation therapy offers no benefit at all.
Key open questions include the durability of the genetic correction beyond 28 days. In vivo base editing does not result in the expansion of corrected cells over time the way ex vivo approaches can; the degree of correction depends entirely on the fraction of hepatocytes the lipid nanoparticles reach on the initial infusion. Whether the therapeutic AAT levels observed at Day 28 persist for months or years in the same patients is the central clinical question the expanded dataset will need to answer to validate the accelerated approval pathway.
It is also unclear whether a single dose will prove sufficient at the optimal biological dose, or whether a redosing strategy will be required. Beam has not yet disclosed the optimal dose selected for the pivotal-stage expansion cohort. The company stated it plans to enroll approximately 50 additional patients at that dose to support the future BLA submission, but the specific dose and the timeline for BLA submission have not been publicly confirmed.
The competitive landscape is unsettled. STAT News reported in March 2025 that Prime Medicine — a company founded using related gene-editing technology from the same laboratory as Beam — has also announced intentions to develop an AATD program, triggering a licensing dispute with Beam over intellectual property rights. The outcome of that dispute could affect the broader competitive dynamics of the AATD gene editing field. Intellia Therapeutics discontinued its own AATD program in late 2025, narrowing the field but not eliminating it.
Analysis
The distinction that makes BEAM-302 historically significant is not scale or speed — it is type. Previous gene editing therapies, including the two approved sickle cell treatments using CRISPR and base editing, function primarily by disrupting or inactivating genes rather than correcting them. They work by deleting or disabling a sequence, typically to reactivate a fetal gene or remove a harmful protein-coding region entirely.
BEAM-302 attempts something fundamentally different: it rewrites a single adenine to guanine in a gene that is otherwise functional, restoring rather than removing. This approach preserves the natural physiological regulation of AAT production — including the body’s ability to upregulate AAT output during inflammation and infection, a feature no existing protein replacement therapy can replicate. If the genetic correction proves durable, treated patients would effectively carry a functional copy of the gene in a fraction of their liver cells for the remainder of their lives.
The clinical significance of exceeding the 11 micromolar protective threshold — a benchmark established through decades of observational research in patients with various AATD genotypes — gives the results a quantitative foundation that early gene therapy programs often lacked. The FDA’s willingness to discuss an accelerated approval pathway based on that biomarker suggests regulators view the mechanistic rationale as credible.
The outstanding uncertainties are substantial but addressable. Durability over months and years is the dominant question, and it is one the existing trial participants can answer simply through continued observation. The liver disease cohort, once enrolled, will determine whether the therapy’s mechanism — reducing Z-AAT accumulation in hepatocytes — translates to histological or functional improvements in patients whose most urgent medical need is not pulmonary but hepatic.
The Q1 2026 readout will not answer all of these questions. But it should establish whether the single-dose correction levels seen at Day 28 persist at six or twelve months in the earliest-treated patients, which is the data point the FDA agreed could serve as the basis for an accelerated approval submission. If those numbers hold, BEAM-302 would likely become the first gene editing therapy to correct — rather than disrupt or remove — a disease-causing mutation in a commercially approved product.